Abstract
Antibodies towards the N-terminal region of the (β-amyloid peptide bind to β-amyloid fibrils, leading to their disaggregation. We generated anti-aggregating (β-amyloid antibodies using filamentous phages displaying the only four amino acids EFRH found to be the main regulatory site for β-amyloid formation. In order to overcome the low permeability of the blood brain barrier for targeting ’anti-aggregating’ mAbs to the βA plaques in the brain, we applied antibody engineering methods to minimize the size of the mAbs while maintaining their biological activity. We found that single-chain antibodies displayed on the surface of the phage are capable of entering the central nervous system (CNS). The feasibility of these novel strategies for the production and targeting of anti-aggregating antibodies against [3-amyloid plaques to disease affected regions in the CNS may have clinical potential for treatment of Alzheimer’s disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bastein N, Trudel M, Simard C (1997) Protective immune responses induced by the immunization of mice with recombinant bacteriophage displaying an epitope of the human respiratory syncytical virus. Virology 234: 118–122
Frenkel D, Balass M, Solomon B (1998) N-Terminal EFRH sequence of Alzheimer’s β-amyloid peptide represents the epitope of its anti-aggregation antibodies. J Neuroimmunol 88: 85–90
Frenkel D, Katz O, Solomon B (2000a) Immunization against Alzheimer’s (3-amyloid plaques via EFRH-phage administration. Proc Natl Acad Sci USA 97(21): 11455–11459
Frenkel D, Solomon B, Benhar I (2000b) Modulation of Alzheimer’s β-amyloid neurotoxicity by site-directed single-chain antibody. J Neuroimmunol 106(1–2): 23–31
Levine H III (1993) Thioflavine T interaction with synthetic Alzheimer’s disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2: 404–410
McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348: 552–554
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, m Guido T, Hu K, Huang J, Johnson-Wood K, Khan K et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740): 173–177
Sladowski D, Steer SJ, Clothier RH, Balls M (1993) An improved MTT assay. J Immunol Methods 157(1–2): 203–207
Solomon B, Koppel R, Hanan E, Katzav T (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer (3-amyloid peptide. Proc Natl Acad Sci USA 93:452–455
Solomon B, Koppel R, Frenkel D, Hanan-Aharon E (1997) Disaggregation of Alzheimer (3-amyloid by site-directed mAb. Proc Natl Acad Sci USA 94: 4109–4112
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Wien
About this paper
Cite this paper
Solomon, B., Frenkel, D. (2002). Generation and brain delivery of anti-aggregating antibodies against β-amyloid plaques using phage display technology. In: Jellinger, K.A., Schmidt, R., Windisch, M. (eds) Ageing and Dementia Current and Future Concepts. Journal of Neural Transmission. Supplementa, vol 62. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6139-5_30
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6139-5_30
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83796-2
Online ISBN: 978-3-7091-6139-5
eBook Packages: Springer Book Archive